Katharine Sepp, Co-founder & CEO, Oxalys Pharmaceuticals
P&G is seeking startups for enabling AI tech: Transforming Consumer Insights Research with IoT, audio, and privacy-preserving video and Synthetic Image and Label Data.
Trond Undheim, PhD, Program Director, MIT Startup Exchange; Paula Hammond, PhD, David H. Koch Professor in Engineering and Department Head, Chemical Engineering, MIT; Laura Indolfi, PhD, CEO of PanTher Therapeutics; Peter Sandor, VP, Head of Oncology Marketing Strategy, Astellas.
"A call to automate the automation," Thomas Fuhlbrigge, Global Program Manager, Next Generation Robotics, ABB
IMA SpA makes machines for packaging coffee, tea, cosmetics, pharmaceuticals. The company sales are about USD 700M. They have operations around the world. Customers include Unilever, Novartis, Bigelow. They seek robotics startups for repetitive tasks.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
The 2024 MIT Houston Symposium will gain the insights needed to navigate the dramatic changes driven by global economic forces, emerging technologies, and evolving government policies. This event will explore the transformative power of artificial intelligence (AI), essential workforce development strategies, groundbreaking advancements in manufacturing, shifting international trade patterns, and the impact of recent U.S. legislation on industrial policy.
Please visit the MIT ILP site for the full agenda.